NASDAQ:TSHA

Taysha Gene Therapies Stock Insider Trading

Healthcare > Biotechnology

Buy TSHA

*Your capital is at risk

$5.86

-0.0150 (-0.255%)

At Close: Jul 31, 2026

Taysha Gene Therapies Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -43.25. In total, the insiders bought 17.87M and sold 2.05M TSHA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-43.25
● Buy	17.87M shares
● Sell	2.05M shares
80% Buy Activity Strong Negative Correlation
Sell Signal Medium Confidence Jul 10, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -43.25. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 02, 2025 Buy	Common Stock A-Award	Donenberg Phillip B. Director	Director	56 623 Value: $157.7K
Jun 02, 2025 Buy	Stock Option (right to buy) A-Award	Donenberg Phillip B. Director	Director	113 246 Value: $315.4K
Jun 02, 2025 Buy	Stock Option (right to buy) A-Award	Long Alison S Director	Director	113 246 Value: $315.4K
Jun 02, 2025 Buy	Common Stock A-Award	Long Alison S Director	Director	56 623 Value: $157.7K
Jun 02, 2025 Buy	Stock Option (right to buy) A-Award	Sepp-lorenzino Laura Director	Director	113 246 Value: $315.4K
Jun 02, 2025 Buy	Common Stock A-Award	Sepp-lorenzino Laura Director	Director	56 623 Value: $157.7K
Jun 02, 2025 Buy	Common Stock A-Award	Sepp-lorenzino Laura Director	Director	56 623 Value: $157.7K
Jun 02, 2025 Buy	Stock Option (right to buy) A-Award	Sepp-lorenzino Laura Director	Director	113 246 Value: $315.4K
Jun 02, 2025 Buy	Common Stock A-Award	Long Alison S Director	Director	56 623 Value: $157.7K
Jun 02, 2025 Buy	Stock Option (right to buy) A-Award	Long Alison S Director	Director	113 246 Value: $315.4K
Jun 02, 2025 Buy	Stock Option (right to buy) A-Award	Donenberg Phillip B. Director	Director	113 246 Value: $315.4K
Jun 02, 2025 Buy	Common Stock A-Award	Donenberg Phillip B. Director	Director	56 623 Value: $157.7K
Jun 02, 2025 Buy	Stock Option (right to buy) A-Award	Stalfort John A Iii Director	Director	113 246 Value: $315.4K
Jun 02, 2025 Buy	Common Stock A-Award	Stalfort John A Iii Director	Director	56 623 Value: $157.7K
May 30, 2025 Buy	Common Stock P-Purchase	Manning Paul B 10 Percent Owner	10% Owner	750 000 Value: $2.06M
May 30, 2025 Buy	Common Stock P-Purchase	Manning Paul B 10 Percent Owner	10% Owner	750 000 Value: $2.06M
Mar 11, 2025 Sell	Common Stock F-InKind	Alam Kamran Chief Financial Officer	C-Suite Officer	29 843 Value: $50.4K
Mar 11, 2025 Sell	Common Stock F-InKind	Alam Kamran Chief Financial Officer	C-Suite Officer	29 843 Value: $50.4K
Jan 02, 2025 Buy	Common Stock A-Award	Nolan Sean P. Chief Executive Officer	CEO / President	892 500 Value: $1.65M
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Nolan Sean P. Chief Executive Officer	CEO / President	892 500 Value: $1.65M
Jan 02, 2025 Buy	Common Stock A-Award	Nagendran Sukumar President And Head Of R&d	CEO / President	324 500 Value: $600.3K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Nagendran Sukumar President And Head Of R&d	CEO / President	324 500 Value: $600.3K
Jan 02, 2025 Buy	Common Stock A-Award	Alam Kamran Chief Financial Officer	C-Suite Officer	431 000 Value: $797.4K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Alam Kamran Chief Financial Officer	C-Suite Officer	431 000 Value: $797.4K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Alam Kamran Chief Financial Officer	C-Suite Officer	431 000 Value: $797.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT TAYSHA GENE THERAPIES, INC.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of ...

Read Full Profile Here